Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria

Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria

Bibliographic Details
Main Authors:	Youin Bae, Sung Hun Kang, Ju Ok Park, Gyeong-Hun Park, Jeong-Hee Choi
Format:	Article
Language:	English
Published:	Elsevier 2020-04-01
Series:	Allergology International
Online Access:	http://www.sciencedirect.com/science/article/pii/S132389301930173X

Similar Items

Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria
by: J.H. Choi, et al.
Published: (2020-08-01)

Omalizumab for the management of refractory chronic spontaneous urticaria
by: P C Kathuria, et al.
Published: (2022-01-01)

Omalizumab in treatment-resistant chronic spontaneous urticaria
by: Kiran V Godse
Published: (2011-01-01)

Profile of omalizumab in the treatment of chronic spontaneous urticaria
by: Labrador-Horrillo M, et al.
Published: (2015-08-01)

Omalizumab in chronic spontaneous urticaria: steroid sparing effect
by: Alessia Gatta, et al.
Published: (2018-12-01)

Omalizumab's efficacy and safety against chronic spontaneous urticaria
by: Öner Özdemir
Published: (2023-08-01)

Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy
by: Shuang-Lu Liao, et al.
Published: (2021-03-01)

Chronic spontaneous urticaria treated with omalizumab: report of two cases
by: Giovanna Malara, et al.
Published: (2018-12-01)

Down-titration of omalizumab in a patient with chronic spontaneous urticaria
by: Pinuccia Omodeo
Published: (2018-12-01)

Omalizumab treatment for chronic spontaneous urticaria: data from Turkey
by: Rabia Kara, et al.
Published: (2022-09-01)

Alopecia Areata after Omalizumab Treatment for Chronic Spontaneous Urticaria
by: Eli Magen
Published: (2019-07-01)

Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both
by: Yudi Chen, et al.
Published: (2021-01-01)

Retrospective analysis of the treatment of 61 cases of chronic spontaneous urticaria with omalizumab
by: Shanshan OU, et al.
Published: (2023-04-01)

Long-Term Omalizumab Use, Chronic Spontaneous Urticaria and COVID-19
by: Öner Özdemir
Published: (2024-01-01)

Clinical observation of desloratadine combined with omalizumab in the treatment of chronic spontaneous urticaria
by: Zhiwei SHANG, et al.
Published: (2022-02-01)

Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population
by: Kanokvalai Kulthanan, et al.
Published: (2017-02-01)

Omalizumab in the treatment of chronic spontaneous urticaria – literature review and own experience
by: Joanna Dawicka, et al.
Published: (2016-02-01)

Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria
by: Nadja Højgaard Pedersen, et al.
Published: (2023-07-01)

Omalizumab treatment in patients with severe chronic spontaneous urticaria: consideration from real-life experience in Italy
by: Riccardo Asero
Published: (2018-12-01)

Exploring Machine Learning Techniques to Predict the Response to Omalizumab in Chronic Spontaneous Urticaria
by: Davide Stefano Sardina, et al.
Published: (2021-11-01)

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
by: Thomas B. Casale, et al.
Published: (2023-09-01)

Effective treatment with omalizumab of a patient with spontaneous chronic urticaria and eosinophilic esophagitis
by: Eugenio Provenzano, et al.
Published: (2018-12-01)

Omalizumab treatment in a 12 year-old girl with chronic spontaneous urticaria
by: Giuseppe Fabio Parisi, et al.
Published: (2018-12-01)

Multicentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombia
by: Elizabeth García-Gómez, et al.
Published: (2022-05-01)

Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Common Variable Immunodeficiency
by: Pasquale Comberiati, et al.
Published: (2019-07-01)

Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients
by: Kiran Godse, et al.
Published: (2016-01-01)

Omalizumab Reduces Unplanned Healthcare Interactions in Irish Patients With Chronic Spontaneous Urticaria
by: Katie Ridge, et al.
Published: (2021-12-01)

Urticaria and angioedema as possible reactions of omalizumab
by: Ozlem Ozbagcivan, et al.
Published: (2018-03-01)

Omalizumab for chronic urticaria in Latin America
by: Paul Wilches, et al.
Published: (2016-11-01)

Omalizumab for chronic urticaria in Latin America
by: Paul Wilches, et al.
Published: (2016-01-01)

Mapping the intellectual structure of the research of omalizumab in chronic spontaneous urticaria: A bibliometric analysis
by: Yuxu Yao, MD, et al.
Published: (2024-05-01)

COVID-19 infection in chronic spontaneous urticaria treated with omalizumab: two case reports
by: Angelo Massimiliano D'Erme, et al.
Published: (2023-08-01)

PK/PD modeling to characterize placebo and treatment effect of omalizumab for chronic spontaneous urticaria
by: Elise Oh, et al.
Published: (2023-06-01)

Combined treatment with omalizumab and etanercept in a patient with chronic spontaneous urticaria and rheumatoid arthritis
by: Misbah Noshela Ghazanfar, et al.
Published: (2019-05-01)

Recurrent oedema of the uvula in a patient with chronic spontaneous urticaria successfully treated with omalizumab
by: Alessandro Pannofino
Published: (2018-12-01)

Chronic spontaneous urticaria or autoinflammatory disease? The therapeutic effect of omalizumab in a pediatric patient
by: Maria Cristina Maggio, et al.
Published: (2018-12-01)

Changes of Gut Microbiome in Adolescent Patients with Chronic Spontaneous Urticaria After Omalizumab Treatment
by: Wang M, et al.
Published: (2023-02-01)

Omalizumab for the treatment of chronic spontaneous urticaria: association between body mass index and outcome
by: Irene Russo, et al.
Published: (2022-10-01)

Efficacy of Omalizumab Treatment with Concomitant Antihistamines as Needed for Moderate, Refractory Chronic Spontaneous Urticaria
by: Eustachio Nettis, et al.
Published: (2018-01-01)

Efficacy and safety of omalizumab therapy in urticaria vasculitis
by: Fiorella Petrelli, et al.
Published: (2022-07-01)